Plasma cell leukemia

From WikiMD's WELLNESSPEDIA

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Plasma cell leukemia
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms Fatigue, bone pain, anemia, hypercalcemia, renal failure
Complications Infection, thrombosis
Onset Typically in adulthood
Duration Chronic
Types N/A
Causes Genetic mutations, environmental factors
Risks Multiple myeloma, monoclonal gammopathy of undetermined significance
Diagnosis Blood test, bone marrow biopsy
Differential diagnosis Multiple myeloma, chronic lymphocytic leukemia
Prevention N/A
Treatment Chemotherapy, stem cell transplant, immunotherapy
Medication N/A
Prognosis Poor, with median survival of 7-11 months
Frequency Rare, <1% of all leukemias
Deaths N/A


A rare and aggressive form of leukemia

Plasma cell leukemia (PCL) is a rare and aggressive form of leukemia characterized by the presence of plasma cells in the peripheral blood. It is considered a variant of multiple myeloma, but it is distinguished by its more aggressive clinical course and poorer prognosis.

Classification[edit]

Plasma cell leukemia can be classified into two types:

  • Primary plasma cell leukemia: This form occurs de novo, meaning it arises without a prior history of multiple myeloma.
  • Secondary plasma cell leukemia: This form develops as a progression from pre-existing multiple myeloma.

Pathophysiology[edit]

Plasma cell leukemia is characterized by the proliferation of malignant plasma cells, which are a type of white blood cell responsible for producing antibodies. In PCL, these cells are found in large numbers in the peripheral blood, unlike in multiple myeloma where they are primarily located in the bone marrow.

Clinical Features[edit]

Patients with plasma cell leukemia may present with a variety of symptoms, including:

Diagnosis[edit]

The diagnosis of plasma cell leukemia is made based on the presence of more than 20% plasma cells in the peripheral blood or an absolute plasma cell count greater than 2 x 10^9/L. Diagnostic tests may include:

Treatment[edit]

Treatment for plasma cell leukemia is challenging due to its aggressive nature. Options may include:

Prognosis[edit]

The prognosis for plasma cell leukemia is generally poor, with a median survival of less than one year. Early diagnosis and aggressive treatment are crucial for improving outcomes.

See also[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.